[Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria].
OBJECTIVE
To observe the efficacy and side effect of DA/HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria (PNH).


METHODS
Eight patients with refractory and relapsed PNH were treated with DA/HA regimen chemotherapy. Three patients were treated with DA (DNR 40 mg/d, i.v.drip, the first and the second day; 20 mg/d, i.v.drip, the third day; Ara-C 100 mg/d, i.v.drip, for 5 days) and 5 patients with HA (HHT 2 - 3 mg/d, i.v.drip, for 5 days; Ara-C 100 mg/d, i.v.drip, for 5 days).


RESULTS
All the 8 patients responded well: the PNH clone was diminished in five patients. Hemolysis was remitted in 6 cases. Five patients showed improvement in hematological parameters. The dosage of corticosteroid was decreased in all of them. No serious side effect was revealed.


CONCLUSIONS
DA/HA regimen chemotherapy was safe and effective for refractory and relapsed PNH patients.
Cao
Yan-ran
YR
Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.
Shao
Zong-hong
ZH
Jia
Hai-rong
HR
Sun
Juan
J
Liu
Hong
H
Wu
Yu-hong
YH
Qin
Tie-jun
TJ
Shi
Jun
J
Bai
Jie
J
He
Guang-sheng
GS
Fu
Rong
R
Zhao
Ming-feng
MF
Tu
Hai-feng
HF
Cui
Zhen-zhu
ZZ
Yang
Tian-ying
TY
D000293:Adolescent; D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D017261:Glycosylphosphatidylinositols / Q000032:analysis; D006248:Harringtonines; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006801:Humans; D008297:Male
D017261:Glycosylphosphatidylinositols; D006248:Harringtonines; D003561:Cytarabine; C062500:harringtonin; D003630:Daunorubicin